As reported by Goncalves Silva et al., this inhibitory receptor, together with its natural ligand galectin-9 (Gal-9), constitutes a secretory pathway that can be considered a potential target for AML immunotherapy [112]. This evidence concerns the gene LGALS9 and acute myeloid leukemia.